ScreenerHero

UNCY Unicycive Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · unicycive.com
4.180USD-1.18%Mkt Cap: 114.50M $P/E: —

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a la…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap114.50M USD
Enterprise Value57.07M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-26.55M USD
Revenue/Share—
Last Price4.180 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)2.51
PEG—
EV/EBITDA-1.73
EV/Revenue—
P/S—
P/B2.21
EPS (TTM)-1.72
EPS (Forward)1.69
52W Range
3.7109% of range8.740
52W High8.740 USD
52W Low3.710 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-87.94%
ROA-54.04%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-31.32M USD
CapEx (TTM)24.00K USD
FCF Margin—
FCF Yield-11.11%
Net Debt-60.75M USD
Net Debt/EBITDA1.84
Balance Sheet
Debt/Equity0.01
Current Ratio3.81
Quick Ratio3.28
Book Value/Sh1.91 USD
Cash/Share2.21 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJun 20, 2025
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)28.40 USD
Upside (mean)+579.4%
Target Range13.00 USD – 42.00 USD
13.00+579.4% to mean42.00
# Analysts10
Ownership
Shares Out.27.39M
Float27.21M
Insiders2.26%
Institutions42.26%
Short Interest
Short Ratio5.3d
Short % Float15.44%
Short % Out.15.09%
Shares Short4.20M
Short (prev mo.)4.15M
Technical
SMA 505.073 (-17.6%)
SMA 2006.295 (-33.6%)
Beta1.82
S&P 52W Chg16.45%
Avg Vol (30d)854.96K
Avg Vol (10d)954.50K
Technical Indicators
RSI (14)31.8
MACD-0.2752
MACD Signal-0.2213
MACD Hist.-0.0539
BB Upper5.479 USD
BB Middle4.755 USD
BB Lower4.031 USD
BB Width30.46%
ATR (14)0.2590 USD
Vol Ratio (20d)0.65x